Caenorhabditis elegans-based model systems for antifungal drug discovery

Area of Science:

• Mycology
• Infectious Diseases
• Drug Discovery

Background:

• Invasive fungal infections cause significant illness and death, particularly in vulnerable populations.
• Existing antifungal drugs face challenges like toxicity and emerging resistance, necessitating new treatments.
• Drug discovery is shifting towards complex bioassays, including whole-animal models.

Purpose of the Study:

• To highlight the utility of Caenorhabditis elegans as a model organism for antifungal drug discovery.
• To explore the advantages of using C. elegans for screening potential antifungal compounds.
• To emphasize the potential for identifying novel antifungal agents with improved efficacy and safety profiles.

Main Methods:

• Utilizing Caenorhabditis elegans as a whole-animal model for antifungal screening.
• Assessing both antifungal efficacy and compound toxicity simultaneously in vivo.
• Employing predictive models to enhance compound bioavailability screening in C. elegans.
• Conducting high-throughput screening of chemical libraries against Candida albicans in C. elegans.

Main Results:

• C. elegans effectively models key fungal pathogenesis features, such as filament formation.
• The C. elegans model allows for the simultaneous evaluation of drug efficacy and toxicity.
• This model facilitates the discovery of compounds with novel mechanisms of action.
• Predictive models improve the a priori selection of compounds for screening.

Conclusions:

• Caenorhabditis elegans presents a valuable and cost-effective platform for antifungal drug discovery.
• The C. elegans-based assay enables efficient screening for novel antifungal agents.
• This approach holds significant promise for addressing the unmet need for new antifungal therapies.